Literature DB >> 25929741

Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study.

Valerio Gallotta1, Gabriella Ferrandina2, Vito Chiantera3, Anna Fagotti4, Francesco Fanfani2, Alfredo Ercoli5, Francesco Legge3, Barbara Costantini2, Salvatore Gueli Alletti2, Carolina Bottoni2, Luigi Pedone Anchora2, Camilla Nero2, Giovanni Scambia2.   

Abstract

OBJECTIVE: To assess the feasibility of laparoscopic radical surgery in patients with locally advanced cervical cancer (LACC) who receive chemoradiation therapy (CT/RT).
DESIGN: Prospective phase II study (Canadian Task Force classification II-1). INTERVENTION: Patients with LACC (FIGO stage IB2-III) were evaluated for accrual at the Gynecologic Oncology Unit of Catholic University, Rome/Campobasso. Neoadjuvant CT/RT included whole-pelvic irradiation (total dose, 45.0-50.4 Gy) combined with cisplatin and 5-fluorouracil. Objective response to treatment was evaluated according to Response Evaluation Criteria in Solid Tumors criteria. Laparoscopic radical hysterectomy (RH) plus pelvic and/or aortic lymphadenectomy was attempted within 6 to 8 weeks after CT/RT. The feasibility of laparoscopic RH, as well as the rate, pattern, and severity of early and late postoperative complications, were analyzed.
RESULTS: Between January 2010 and October 2013, a total of 58 patients were enrolled into the study. After CT/RT, 23 patients (39.6%) underwent type B2 RH, 31 (53.4%) underwent type C1 RH, and 4 (6.9%) underwent type C2 RH. Pelvic lymphadenectomy was performed in all cases. Laparoscopic RH was feasible in 55 of 58 cases (feasibility rate, 94.8%). No intraoperative complications were recorded. During the observation period (median, 22 months; range, 5-50 months), there were 28 complications, of which only 21.4% were grade 2 complications and 14.3% were grade 3 complications. As of January 2015, disease recurrence was documented in 4 cases (6.9%).
CONCLUSION: Total laparoscopic radical surgery is feasible in patients with LACC receiving preoperative CT/RT, providing perioperative outcomes comparable to those registered in early-stage disease.
Copyright © 2015 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Laparoscopy; Neoadiuvant chemoradiation; Radical hysterectomy

Mesh:

Substances:

Year:  2015        PMID: 25929741     DOI: 10.1016/j.jmig.2015.04.014

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  4 in total

1.  The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery.

Authors:  A L Valentini; M Miccò; B Gui; M Giuliani; E Rodolfino; A M Telesca; T Pasciuto; A Testa; M A Gambacorta; G Zannoni; V Rufini; A Giordano; V Valentini; G Scambia; R Manfredi
Journal:  Eur Radiol       Date:  2018-01-09       Impact factor: 5.315

2.  The Effect of Neoadjuvant Chemotherapy Combined With Brachytherapy Before Radical Hysterectomy on Stage IB2 and IIA Cervical Cancer: A Retrospective Analysis.

Authors:  Yun Dang; Qing Liu; Lixia Long; Hua Luan; Qingfang Shi; Xunyuan Tuo; Shumei Tuo; Yilin Li
Journal:  Front Oncol       Date:  2021-03-23       Impact factor: 6.244

3.  Paclitaxel Plus Platinum Neoadjuvant Chemotherapy Followed by Surgery Versus Primary Surgery in Locally Advanced Cervical Cancer-A Propensity Score Matching Analysis.

Authors:  Yanan Zhang; Bin Li; Yating Wang; Shuanghuan Liu; Haibo Wang
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

4.  Prognostic Model for Predicting Overall and Cancer-Specific Survival Among Patients With Cervical Squamous Cell Carcinoma: A SEER Based Study.

Authors:  Zhuolin Li; Yao Lin; Bizhen Cheng; Qiaoxin Zhang; Yingmu Cai
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.